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Consumption of pomegranates improves synaptic function in a transgenic
mice model of Alzheimer's disease
Abstract
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by extracellular plaques
containing abnormal Amyloid Beta (Aβ) aggregates, intracellular neurofibrillary tangles containing
hyperphosphorylated tau protein, microglia-dominated neuroinflammation, and impairments in synaptic
plasticity underlying cognitive deficits. Therapeutic strategies for the treatment of AD are currently limited. In
this study, we investigated the effects of dietary supplementation of 4% pomegranate extract to a standard
chow diet on neuroinflammation, and synaptic plasticity in APPsw/Tg2576 mice brain. Treatment with a
custom mixed diet (pellets) containing 4% pomegranate for 15 months ameliorated the loss of synaptic
structure proteins, namely PSD-95, Munc18-1, and SNAP25, synaptophysin, phosphorylation of Calcium/
Calmodulin Dependent Protein Kinase IIα (p-CaMKIIα/ CaMKIIα), and phosphorylation of Cyclic AMP-
Response Element Binding Protein (pCREB/CREB), inhibited neuroinflammatory activity, and enhanced
autophagy, and activation of the phophoinositide-3-kinase-Akt-mammalian target of rapamycin signaling
pathway. These neuroprotective effects were associated with reduced β-site cleavage of Amyloid Precursor
Protein in APPsw/Tg2576 mice. Therefore, long-term supplementation with pomegranates can attenuate AD
pathology by reducing inflammation, and altering APP-dependent processes.
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ABSTRACT
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder 
characterized by extracellular plaques containing abnormal Amyloid Beta (Aβ) 
aggregates, intracellular neurofibrillary tangles containing hyperphosphorylated 
tau protein, microglia-dominated neuroinflammation, and impairments in 
synaptic plasticity underlying cognitive deficits. Therapeutic strategies for the 
treatment of AD are currently limited. In this study, we investigated the effects of 
dietary supplementation of 4% pomegranate extract to a standard chow diet on 
neuroinflammation, and synaptic plasticity in APPsw/Tg2576 mice brain. Treatment 
with a custom mixed diet (pellets) containing 4% pomegranate for 15 months 
ameliorated the loss of synaptic structure proteins, namely PSD-95, Munc18-1, and 
SNAP25, synaptophysin, phosphorylation of Calcium/Calmodulin Dependent Protein 
Kinase IIα (p-CaMKIIα/ CaMKIIα), and phosphorylation of Cyclic AMP-Response 
Element Binding Protein (pCREB/CREB), inhibited neuroinflammatory activity, and 
enhanced autophagy, and activation of the phophoinositide-3-kinase-Akt-mammalian 
target of rapamycin signaling pathway. These neuroprotective effects were associated 
with reduced β-site cleavage of Amyloid Precursor Protein in APPsw/Tg2576 mice. 
Therefore, long-term supplementation with pomegranates can attenuate AD pathology 
by reducing inflammation, and altering APP-dependent processes.
INTRODUCTION
Alzheimer’s Disease (AD) is a progressive 
neurodegenerative disorder characterized clinically by 
progressive cognitive and memory impairments [1]. 
Recent epidemiological studies have shown that at least 
36.5 million individuals are affected by AD worldwide, 
with new AD diagnosis reported every 7 seconds [2]. 
Ageing represents the main risk factor for AD and its 
prevalence is expected to increase exponentially with age 
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[1, 3-5]. The aetiology and exact neuropathogenesis of AD 
remain unclear. However, AD is thought to be a complex 
multi-factorial disorder, and no effective therapeutic agent 
is available to slow down or prevent disease progression 
[6, 7]. 
The main pathological hallmarks of AD is 
the formation of extracellular Amyloid-Beta (Aβ) 
deposits called senile plaques, and twisted intracellular 
neurofibrillary tangles containing hyperphosphorylated 
tau, a microtubular protein [8]. Aβ plaques can 
induce synaptic loss in the neocortex and limbic 
system, leading to neuronal injury. Aβ can also induce 
neuronal damage through activation of microglia, the 
resident immunoregulatory cells in the brain, leading 
to the production and release of neurotoxic and pro-
inflammatory cytokines, such as Tumor Necrosis Factor 
(TNF)-α, Interleukin (IL)-1β, and highly volatile free 
radicals [9]. Microglial activation represents a critical 
process to facilitate the clearance of Aβ from the brain 
via endocytosis [10, 11]. Therefore, therapeutic strategies 
targeting neuroinflammation and microglial activation are 
highly desirable [12-15].
The generation of Aβ is dependent on the 
proteolytic processing of Amyloid Precursor Protein [16] 
by α-secretase, β-secretase (BACE1), and γ-secretase. 
α-secretase is responsible for the cleavage of APP at 
the luminal region, thus preventing the formation of 
neurotoxic Aβ aggregates and plaques [17, 18]. BACE1 
is responsible for the cleavage of full length APP on the 
N-terminus of Aβ, consequently leading to the formation 
of smaller soluble ectodomain fragment (sAPP-β), and 
a larger C-terminal fragment (C99) [19-22]. γ-secretase 
catalyses the formation of Aβ from the C99 fragment [23]. 
Given the significance of Aβ in AD pathology, therapeutic 
strategies aimed at interfering with the processing of APP 
are warranted.
Synaptic dysfunction represents another pathological 
presentation of AD. Synaptic plasticity is crucial for the 
maintenance of optimal memory and learning [24-26]. 
Since impairments in synaptic plasticity precede synaptic 
loss, changes to synaptic regulatory protein may represent 
an important biomarker for disease progression and 
cognitive impairments [27, 28]. An important example 
is Mammalian Target Of Rapamycin (mTOR), a kinase 
associated with the maintenance of synaptic plasticity by 
modulating the anabolism of protein [29].
Pomegranates (Punica granatum Linn.) are 
composed of high concentrations of polyphenols compared 
to other fruits and vegetables [30-43]. Pomegranates 
have been extensively used for the treatment of several 
degenerative diseases in Unani, Ayurvedic and Chinese 
systems of medicine [44]. Dietary supplementation 
of pomegranate juice attenuated neurodegeneration in 
neonatal mice subjected to maternal hypoxic-ischemic 
brain injury [45, 46]. We and others have previously 
shown that pomegranate supplementation with diet 
significantly reduced oxidative stress in brain [47-
49]. This effect of pomegranate was likely through 
inhibition of Aβ accumulation, which in turn significantly 
attenuated oxidation of lipid and protein, restored 
Acetylcholinesterase (AChE) activity, maintained 
endogenous antioxidant capacity at near physiological 
levels in brain tissues of APPsw/Tg2576 mice, and 
improved spatial learning deficits [47-49]. 
The Tg2576 mice express APP KM670/671NL 
Swedish mutation, and demonstrates progressive age-
dependent behavioural deficits associated with increased 
Aβ deposition. Moreover, this transgenic mice model 
exhibit decreased motor coordination, increased learning 
and memory deficits, and elevations in oxidative stress 
markers. Previous studies have identified significant 
memory impairment, and hippocampal neurodegeneration 
in Tg2576 mice. The current study explores the effect 
of pomegranate supplementation on stress in the 
brain, synaptic plasticity, neuroinflammation, and Aβ 
production in the AD transgenic mice, and examines 
potential disease-related modifications to the expression 
of synaptic plasticity-related proteins, activation of the 
PI3K/Akt/mTOR pathway, neuroinflammation, and altered 
amyloidogenic processing. 
RESULTS
Long-term supplementation with 4% 
pomegranates improved synaptic structure 
protein in APPsw/Tg 2576
Numerous studies have shown that the expression of 
synaptic structural protein is reduced in the brains of AD 
mice compared to wild-type controls [50, 51]. We have 
shown that the protein expression of PSD-95, Munc18-
1, SNAP25, synaptophysin, p-CaMKIIα/ CaMKIIα, and 
pCREB/CREB were significantly increased (p < 0.05) in 
the brain in APPsw/Tg 2576 receiving a diet supplemented 
with 4% pomegranates for 15 months than in APPsw/Tg 
2576 mice receiving a standard chow diet (Figure 1). 
We also assessed the mRNA expression of genes 
encoding for two important neurotrophic factors, BDNF 
and IGF-1 (Figure 2). Our data shows that both BDNF and 
IGF-1 are significantly increased in the brain by 15 months 
of treatment with a 4% pomegranate diet compared to 
APPsw/Tg 2576 mice receiving a standard chow diet.
Long-term supplementation with 4% 
pomegranates reduces neuroinflammation in 
APPsw/Tg 2576
It is well established that neuroinflammation 
plays a pivotal role in the pathogenesis of AD [12-15]. 
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Figure 1: Synaptic structural proteins in brain homogenates detected by Western blot analysis. The levels of PSD-95, 
Munc18-1, SNAP25, synaptophysin, p-CaMKIIα/ CaMKIIα, and pCREB/CREB in the brains of mice fed 4% pomegranate diet for 15 
months. Treatment I: Wild type (non-transgenic) control of the APPsw mice fed with regular diet; Treatment II: APPsw mice also fed 
with regular diet; and Treatment III: APPsw mice fed with 4% pomegranate fruit diet. A. The blot shown is representative tracings of an 
experiment done six times. B. Graphs are mean ± S.E brains from tissue obtained from six rodents for each treatment group. Each bar of 
the quantification graph represents the corresponding band for each age group. Significance *p < 0.01 compared to wild-type mice fed with 
regular diet, #p < 0.01 compared to APPsw transgenic mice fed with regular diet. 
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We examined whether long-term treatment with 4% 
pomegranates attenuated neuroinflammatory activity in 
APPsw/Tg 2576. To determine this, we quantified the 
expression of inflammatory genes in the brain. Our data 
shows that the expression of tnf-α, il-1β, iNOS, ccl2, and 
il-10 were significantly decreased by diet supplemented 
with 4% pomegranates for 15 months (p < 0.05) (Figure 
2). 
Figure 2: mRNA expression of genes encoding for neurotrophic factors and proinflammatory markers. Treatment I: 
Wild type (non-transgenic) control of the APPsw mice fed with regular diet; Treatment II: APPsw mice also fed with regular diet; and 
Treatment III: APPsw mice fed with 4% pomegranate fruit diet. The levels of two important neurotrophic factors, BDNF and IGF-1, and 
the proinflammatory cytokines, tnf-α, il-1β, iNOS, ccl2, and il-10, in the brains of mice fed 4% pomegranate diet for 15 months were 
determined using real-time polymerase chain reactions. Graphs are mean ± S.E brains from tissue obtained from six rodents for each 
treatment group. Significance *p < 0.01 compared to wild-type mice fed with regular diet, #p < 0.01 compared to APPsw transgenic mice 
fed with regular diet.
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Autophagy is enhanced by long-term 
supplementation with 4% pomegranates in 
APPsw/Tg 2576
Apart from the improvements in synaptic protein 
expression and inhibition of neuroinflammation, we 
assessed the effects of 4% pomegranate supplementation 
on autophagy. We observed that dietary supplementation 
with 4% pomegranates significantly induced autophagy, as 
shown by increased protein expression of Beclin-1 (bcl1) 
and Lipidated LC-3 (LC-3 type II) (p < 0.05) (Figure 3).
Figure 3: Protein expression of autophagic markers following long-term supplementation with 4% pomegranates 
in APPsw/Tg 2576. The levels of autophagic markers, LC3 and bcl1, in the brains of mice fed 4% pomegranate diet for 15 months 
were determined using western blot analysis. Treatment I: Wild type (non-transgenic) control of the APPsw mice fed with regular diet; 
Treatment II: APPsw mice also fed with regular diet; and Treatment III: APPsw mice fed with 4% pomegranate fruit diet. A. The blot 
shown is representative tracings of an experiment done six times. B. Graphs are mean ± S.E brains from tissue obtained from six rodents 
for each treatment group. Each bar of the quantification graph represents the corresponding band for each age group. Significance *p < 0.01 
compared to wild-type mice fed with regular diet, #p < 0.01 compared to APPsw transgenic mice fed with regular diet.
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The PI3K/Akt/mTOR signaling pathway is 
activated in APPsw/Tg 2576 treated with 4% 
pomegranates for 15 months
The activation of protein translation by the PI3K/
Akt/mTOR signaling pathway is a key regulator of 
synaptic plasticity [52]. We assessed the effect of 
supplementation with 4% pomegranates on activation of 
the PI3K and mTOR by determining the phosphorylation 
levels of Akt and p70 S6 kinase (p70S6K) using 
immunoblotting. Our data shows that phosphorylation 
of Akt, mTOR and p70S6K were significantly increased 
in the brain of 4% pomegranate-treated APPsw/Tg 2576 
mice compared to APPsw/Tg 2576 mice receiving a 
standard chow diet (p < 0.05) (Figure 4). 
Treatment with 4% pomegranates lowered 
amyloidogenic processing of APP in APPsw/Tg 
2576 after 15 months
 We also investigated the effect of a 4% pomegranate 
diet on APP processing by Western blot (Figure 5). 
Increased APP anabolism may stimulate APP secretion. 
Therefore, we determined the effect of 4% pomegranate 
diet on full-length APP levels. We used a polyclonal 
carboxyl-terminal APP antibody that is specific to both 
Carboxyl-Terminal Fragment β (CTFβ) and Carboxyl-
Terminal Fragment α (CTFα). No significant difference 
was observed on APP steady-state protein expression 
in the brains of APPsw/Tg 2576 fed standard chow 
diet, and APPsw/Tg 2576 mice administered a 4% 
pomegranate diet. This suggests that pomegranates and 
their constituents do not influence APP synthesis. BACE1 
is responsible for the proteolytic cleavage of full length 
APP to form sAPPβ and CTFβ. We observed a significant 
increase in BACE1, sAPPβ, and CTFβ expression in the 
brains of APPsw/Tg 2576 compared to wild-type mice 
(p< 0.05). After treatment with a 4% pomegranate diet, 
the expression of BACE1, sAPPβ, and CTFβ in APPsw/
Tg 2576 mice was significantly decreased after 15 months 
(p < 0.05). 
CTFα is produced as a by-product of α-secretase 
cleavage, which is regulated by the metalloproteases, 
ADAM10 and ADAM17 [53-59]. The protein expression 
of CTFα was significantly increased by more than 2-fold 
in APPsw/Tg 2576 mice brains compared with wild-type 
controls (p < 0.05). However, no significant difference 
on the levels of CTFα, ADAM10 and ADAM17 was 
observed after pomegranate treatment. This suggests that 
a pomegranate-rich diet has no effect on the modulation of 
the α-secretase pathway.
DISCUSSION
The present study demonstrated for the first time 
that pomegranate diet administered for 15 months 
enhanced synaptic plasticity by increasing the expression 
of synaptic proteins, including PSD-95, Munc18-1, 
SNAP25, synaptophysin, p-CaMKIIα/ CaMKIIα, and 
pCREB/CREB, inhibited neuroinflammation, promoted 
autophagy, activated PI3K-Akt-mTOR signaling pathway, 
and altered APP processing in APPsw/Tg 2576 mice. 
The beneficial effects of fruits and vegetables in 
health and ageing have been well emphasized. However, 
few studies have demonstrated the neuroprotective effects 
of pomegranate consumption in preclinical and clinical 
trials for AD. Pomegranates have been shown to consist 
of numerous phytochemicals, with potent antioxidant 
and anti-inflammatory properties. Indeed, our qualitative 
analysis using high precision liquid chromatography 
(HPLC) has shown that pomegranate extracts contain 
active components in significant amounts of ellagitannin, 
such as punicalin and punicalagin, and flavonoids, such as 
kaempferol and quercetin derivatives (Data not shown). 
Apart from demonstrating potent antioxidant and anti-
inflammatory properties, ellagic acid and punicalagin, are 
β-secretase inhibitors [60]. As well, recent studies have 
suggested that quercetin may exert its beneficial effects 
independent of its antioxidant properties. Quercetin can 
also modulate pathways associated with mitochondrial 
biogenesis, mitochondrial membrane potential, oxidative 
respiration and ATP anabolism, intra-mitochondrial redox 
status, and subsequently, mitochondria-induced apoptosis 
[61]. Taken together, the active phytochemicals present 
in pomegranate extracts possess beneficial effects on 
brain function and can mitigate different hallmarks of 
neurodegeneration.
We and others have previously shown that dietary 
pomegranate supplementation can attenuate chronic 
oxidative stress in APPsw/Tg 2576 mice, reduce 
acetylcholinesterase activity and plasma Aβ1-40 and Aβ1-
42 levels, and ameliorate memory and anxiety-related 
behavioural deficits, and improve spatial learning ability 
in vivo, consistent with our findings [47-49]. Biological 
extracts derived from the pomegranate rind have been 
shown to inhibit BACE1 activity in vitro. Pomegranate 
consumption has also been shown to improve brain 
function in several neurodegenerative disease models 
[62]. For instance, pomegranates attenuated 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative 
stress and apoptosis in neuronal cells [63]. Reduced 
brain damage was also observed in postnatal day 7 
pups exposed maternally to hypoxic insult [45, 46, 64]. 
Improvements in motor behaviour have also been reported 
in mice exposed to cytotoxic levels of proton radiation 
following pomegranate consumption [65]. Ellagic acid 
possesses potent neuroprotective effects through its free 
radical scavenging properties, iron chelation, activation 
Oncotarget64595www.impactjournals.com/oncotarget
Figure 4: mTOR signaling pathway in brain homogenates detected by Western blot analysis. The levels Akt, mTOR 
and p70S6K, and their phosphorylated forms in the brains of mice fed 4% pomegranate diet for 15 months. Treatment I: Wild type (non-
transgenic) control of the APPsw mice fed with regular diet; Treatment II: APPsw mice also fed with regular diet; and Treatment III: 
APPsw mice fed with 4% pomegranate fruit diet. A. The blot shown is representative tracings of an experiment done six times. B. Graphs 
are mean ± S.E brains from tissue obtained from six rodents for each treatment group. Each bar of the quantification graph represents the 
corresponding band for each age group. Significance *p < 0.01 compared to wild-type mice fed with regular diet, #p < 0.01 compared to 
APPsw transgenic mice fed with regular diet.
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Figure 5: BACE1 and APP processing in brain homogenates detected by Western blot analysis. The levels APP, BACE1, 
CTFα, CTFβ, sAPPβ, ADAM10 and ADAM17 in the brains of mice fed 4% pomegranate diet for 15 months. Treatment I: Wild type 
(non-transgenic) control of the APPsw mice fed with regular diet; Treatment II: APPsw mice also fed with regular diet; and Treatment III: 
APPsw mice fed with 4% pomegranate fruit diet. A. The blot shown is representative tracings of an experiment done six times. B.Graphs 
are mean ± S.E brains from tissue obtained from six rodents for each treatment group. Each bar of the quantification graph represents the 
corresponding band for each age group. Significance *p < 0.01 compared to wild-type mice fed with regular diet, #p < 0.01 compared to 
APPsw transgenic mice fed with regular diet.
Oncotarget64597www.impactjournals.com/oncotarget
of different cell signaling pathways, and mitigation of 
mitochondrial dysfunction.
Synaptic loss represents another pathological 
hallmark in AD. It is well established that alterations in 
the expression of synaptic proteins precedes neuronal loss 
in AD [66-69]. Therefore, we analyzed the changes in 
protein expression of several important synaptic proteins 
associated with maintenance of normal plasticity. We 
found a significant reduction in the presynaptic marker 
synaptophysin and postsynaptic marker PSD-95 in APPsw/
Tg 2576 mice after 15 months, and supplementation with 
a 4% pomegranate diet upregulated the expression of 
these proteins. Increased calcium influx through activated 
N-methyl-D-aspartate (NMDA) receptors induces 
autophosphorylation of Calcium/Calmodulin-Dependent 
Protein Kinase II (CaMKII), and enhances translocation of 
CaMKII to the post-synapse. This leads to the activation 
of Cyclic AMP-Response Element Binding Protein 
(CREB). This nuclear transcription factor is associated 
with the formation of long-term memory [70-75]. We 
found that the ratio of pCaMKIIα/CaMKIIα and pCREB/
CREB declined in APPsw/Tg 2576 mice at 15 months 
compared to wild-type mice. However, supplementation 
with 4% pomegranates significantly improved the ratio 
of pCaMKIIα/CaMKIIα and pCREB/CREB declined in 
APPsw/Tg 2576 mice. Our data collectively suggests that 
a pomegranate-rich diet may attenuate deficits in memory 
and cognition through upregulation of signalling pathways 
associated with synaptic plasticity.
Inflammation has been shown to represent a double-
edged sword in AD pathogenesis - it is deleterious to 
neurons, but is necessary to facilitate the clearance of 
neurotoxic Aβ deposits [76]. Upregulation of important 
inflammatory transcripts, tnf-α, il-1β, iNOS, ccl2, and 
il-1 were observed in APPsw/Tg 2576 mice compared 
to wild-type mice. However, supplementation with 
4% pomegranate diet reduced the expression of these 
proinflammatory gene transcripts. We also examined 
whether the anti-inflammatory effects of a pomegranate 
diet may be due to an autophagic-dependent effect. Our 
data shows that 4% pomegranate diet increased the 
protein expression of bcl1 and LC-3 type II. Bcl1 is an 
essential protein that enhances microglial phagocytosis, 
and autophagy is crucial for the catabolism of abnormal 
Aβ aggregates by activated microglial cells in the brain 
[77-80]. 
Another protein associated with synaptic plasticity is 
mTOR [81, 82]. Increased calcium influx through activated 
NMDA receptors can activate mTOR, thus promoting the 
anabolism of protein, including NR1, CaMKIIα, PSD-95, 
Arc, and protein kinase C isoform protein kinase M zeta, 
to stimulate synaptic plasticity [82-89]. Deregulation of 
mTOR signalling has been associated with cognitive and 
behavioural deficits [90-95]. Increased APP processing 
and the Aβ peptides can inhibit the PI3K-Akt-mTOR 
pathway, and reduced mTOR activity has been reported 
in both APPsw/Tg 2576 mice and human AD patients [96-
116]. Likewise, we found that phosphorylation of mTOR 
was significantly decreased in 15 month old APPsw/Tg 
2576 mice. These pathological changes were improved 
following treatment with 4% pomegranate diet. Therefore, 
another mechanism by which pomegranates may improve 
synaptic function may be through activation of the PI3K-
Akt-mTOR pathway.
We also investigated whether a pomegranate diet can 
change the proteolytic processing of APP, by measuring 
the protein expression of BACE1. In line with previous 
studies, we found that BACE1 protein levels were 
significantly increased 15 month old APPsw/Tg 2576 mice 
compared to wild-type controls [62]. Treatment with 4% 
pomegranates significantly reduced BACE1 expression. 
Therefore, BACE1 inhibition may represent a valuable 
target for reducing Aβ levels in AD [117]. Additionally, the 
protein expression of sAPPβ and CTFβ, were also reduced 
15 month old APPsw/Tg 2576 mice exposed to 4% 
pomegranate diet. These results provide additional support 
for the inhibitory effects of pomegranate consumption of 
BACE1 activity in AD.
The proteolytic cleavage of APP is initiated 
non-amyloidogenically by α-secretase. ADAM10 and 
ADAM17 are two main enzymes with α-secretase activity 
[118-120]. Although ADAM10 is necessary for APP 
α-secretase cleavage, ADAM17 may also be involved, 
although it is not crucial [121]. No significant difference in 
the expression of ADAM10 and ADAM17 were observed 
between 15 month old APPsw/Tg 2576 mice and wild-
type mice. An increase in CTFα level observed in the 
APPsw/Tg 2576 mice compared to wild-type mice may be 
due to increased levels of APP, the α-secretase substrate, 
or α-secretase activity in APPsw/Tg 2576 mice. The 
expression of ADAM10, ADAM17, and CTFα, remained 
unchanged, following treatment with 4% pomegranates, 
suggesting that α-secretase activity is independent of 
pomegranate-mediated APP processing.
In conclusion, this study has demonstrated for 
the first time that long-term supplementation with a 4% 
pomegranate diet can enhance synaptic plasticity in 
APPsw/Tg 2576 mice, leading to reduced cerebral Aβ 
levels, cleavage of CTFβ and sAPPβ, and BACE1 protein 
expression. Together with other mechanisms, such as 
inhibition of neuroinflammation, and increased autophagy, 




Fresh pomegranate fruits were collected from Al-
Jabal Al-Akdhar farms, Oman. Then, pomegranates were 
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frozen (-40°C) for 5 days. After that, the samples were 
ground into a fine powder using a coffee grinder.
Diet preparation for the animals
The ground pomegranates were sent to USA to 
prepare the diet for the mice. The diet was prepared by 
mixing the pomegranate (4%) with regular diet as per 
National Institutes of Health, USA protocol by Research 
Diet Inc, NJ, USA. 
Animals and treatment
Twelve transgenic female (APPsw/Tg 2576) and 6 
wild-type control (non-transgenic) mice (Taconic form, 
NY, USA) were used. Animals were quarantined for 7 
days after shipping and individually housed in plastic 
cages in an animal room, which was maintained at a 
temperature of 22±2°C, a relative humidity of 50±10%, 
and a 12-h light/dark automatic light cycle (light: 08:00-
20:00 h). Tap water was offered ad libitum throughout the 
study. The study was approved by the Animal Care and 
Use Committee of the Sultan Qaboos University, Oman 
(SQU/AEC/2010-11/3). 
All these animals are free from pathogens and 
viruses. Experimental period commenced from the 
age of 4 months. The animals were divided into three 
groups: Treatment I: Wild type (non-transgenic) control 
of the APPsw mice fed with regular diet; Treatment II: 
APPsw mice also fed with regular diet; and Treatment III: 
APPsw mice fed with 4% pomegranate fruit diet. These 
experimental and control mice were fed a 4% pomegranate 
or control diet for 15 months. All animal experiments in 
the present study were complied with the Animal Care and 
Use Committee of the Sultan Qaboos University, Oman.
Tissue collection
The brains were carefully removed, and 
homogenization in 9 volumes (1:9 w/v) of cold saline, and 
centrifugation for supernatant collection. The samples of 
the brain were stored at −80°C until measurement.
Reverse transcription and quantitative PCR for 
analysis of gene transcripts
For the gene expression studies RNA was extracted 
from treated human astrocytes and neurons using the 
RNeasy mini kits (Qiagen, Hilden, Germany). The cDNA 
was prepared using the SuperScript III First-Strand 
Synthesis System and random hexamers (Invitrogen 
Corporation). Q-PCR was carried out using the Mx3500P 
Real-Time PCR system (Stratagene, NSW, Australia) 
with the Taqman gene expression assays of mouse tumour 
necrosis factor-α (tnf-α), interleukin 1-β (il-1β), inducible 
nitric oxide synthase [122], chemokine (C-C motif) 
ligand 2 (ccl2), interleukin 1-β (il-10), brain-derived 
neurotrophic factor (bdnf), insulin-like growth factor 
(igf)-1, and glyceraldehyde 3-phosphate dehydrogenase 
(gapdh) (all from Life Technologies). at 4°C. The 
Western blotting
The brains of animals were dissected on ice and 
immediately processed. Briefly, hippocampal tissue were 
homogenized in RIPA buffer (50 mM, Tris-Cl, pH 7.5, 
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
and 1% SDS), supplemented with a protease inhibitor 
cocktail (Sigma-Aldrich P8340) and phosphatase 
inhibitors (50 mM NaF, 1 mM Na3VO4 and 30 μM 
Na4P207), using a Potter homogenizer and then passed 
sequentially through different calibre syringes. Protein 
samples were centrifuged at 14000 rpm at 4ºC twice 
for 15 min [26]. Protein concentration was determined 
using the BCA Protein Assay Kit (Pierce Biotechnology, 
Rockford, IL). 20 µg of hippocampal samples were 
resolved by 10% SDS-PAGE and transferred to a PVDF 
membrane. The reactions were followed by incubation 
with a primary antibody; then a secondary anti-goat 
peroxidase conjugated antibody (Pierce) was used and 
developed using an ECL kit (Western Lightning Plus ECL, 
PerkinElmer).
Statistical analysis
Results are expressed as mean ± standard error. 
Data were analysed by one-way ANOVA, followed by 
Bonferroni’s post hoc test. p≤0.05 was considered as 
statistically significant. Statistical analysis was performed 
using Prism software (GraphPad Software Inc).
ACKNOWLEDGMENTS
NB is the recipient of an Alzheimer’s Australia 
Viertel Foundation and National Health and Medical 
Research Centre Postdoctoral Research Fellowship at the 
University of New South Wales. The authors thank the 
Rebecca Cooper Medical Research Foundation for their 
ongoing financial support. 
CONFLICTS OF INTEREST
The authors declare no conflict of interests in 
regards to this manuscript. 
GRANT SUPPORT
This work was supported by a research grant from 
Oncotarget64599www.impactjournals.com/oncotarget
the Research Council Oman (RC/AGR/Food/11/01).
Authors’ Contribution
NB and MME designed and conducted all the 
experiments and wrote the manuscript. AP, SA, TM, 
JT, LO, and PS provided conceptual help and reagents 
throughout experimentation. SS contributed to specific 
experimental designs. NB, MME, and GJG were involved 
in conception and design, data analysis and interpretation, 
manuscript writing and final approval of the manuscript.
REFERENCES
1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B, 
Alzheimer Disease I. The worldwide economic impact of 
dementia 2010. Alzheimers Dement. 2013; 9: 1-11 e3. doi: 
10.1016/j.jalz.2012.11.006.
2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri 
CP. The global prevalence of dementia: a systematic review 
and metaanalysis. Alzheimers Dement. 2013; 9: 63-75 e2. 
doi: 10.1016/j.jalz.2012.11.007.
3. Albanese E, Lombardo FL, Prince MJ, Stewart R. Dementia 
and lower blood pressure in Latin America, India, and 
China: a 10/66 cross-cohort study. Neurology. 2013; 81: 
228-35. doi: 10.1212/WNL.0b013e31829bfe66.
4. Albanese E, Taylor C, Siervo M, Stewart R, Prince MJ, 
Acosta D. Dementia severity and weight loss: a comparison 
across eight cohorts. The 10/66 study. Alzheimers Dement. 
2013; 9: 649-56. doi: 10.1016/j.jalz.2012.11.014.
5. Prince MJ. Dementia in China: east-west collaboration 
bears fruit. Lancet. 2013; 381: 1967-8. doi: 10.1016/S0140-
6736(13)60770-9.
6. Gardner RC, Valcour V, Yaffe K. Dementia in the oldest 
old: a multi-factorial and growing public health issue. 
Alzheimers Res Ther. 2013; 5: 27. doi: 10.1186/alzrt181.
7. Licastro F, Porcellini E, Forti P, Buscema M, Carbone I, 
Ravaglia G, Grossi E. Multi factorial interactions in the 
pathogenesis pathway of Alzheimer’s disease: a new risk 
charts for prevention of dementia. Immun Ageing. 2010; 7 
Suppl 1: S4. doi: 10.1186/1742-4933-7-S1-S4.
8. Zetterberg H, Blennow K. Cerebrospinal fluid biomarkers 
for Alzheimer’s disease: more to come? J Alzheimers Dis. 
2013; 33 Suppl 1: S361-9. doi: 10.3233/JAD-2012-129035.
9. Wyss-Coray T, Rogers J. Inflammation in Alzheimer 
disease-a brief review of the basic science and clinical 
literature. Cold Spring Harb Perspect Med. 2012; 2: 
a006346. doi: 10.1101/cshperspect.a006346.
10. Liu XH, Geng Z, Yan J, Li T, Chen Q, Zhang QY, Chen ZY. 
Blocking GSK3beta-mediated dynamin1 phosphorylation 
enhances BDNF-dependent TrkB endocytosis and the 
protective effects of BDNF in neuronal and mouse models 
of Alzheimer’s disease. Neurobiol Dis. 2015; 74: 377-91. 
doi: 10.1016/j.nbd.2014.11.020.
11. Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, Li Y, Scott 
MJ, Xiao G, Li S, Fan L, Billiar TR, Wilson MA, et al. 
Macrophage endocytosis of high-mobility group box 1 
triggers pyroptosis. Cell Death Differ. 2014; 21: 1229-39. 
doi: 10.1038/cdd.2014.40.
12. Zou C, Shi Y, Ohli J, Schuller U, Dorostkar MM, Herms 
J. Neuroinflammation impairs adaptive structural plasticity 
of dendritic spines in a preclinical model of Alzheimer’s 
disease. Acta Neuropathol. 2016; 131: 235-46. doi: 
10.1007/s00401-015-1527-8.
13. Minter MR, Taylor JM, Crack PJ. The contribution of 
neuroinflammation to amyloid toxicity in Alzheimer’s 
disease. J Neurochem. 2016; 136: 457-74. doi: 10.1111/
jnc.13411.
14. Wang SW, Yang SG, Liu W, Zhang YX, Xu PX, Wang 
T, Ling TJ, Liu RT. Alpha-tocopherol quinine ameliorates 
spatial memory deficits by reducing beta-amyloid 
oligomers, neuroinflammation and oxidative stress in 
transgenic mice with Alzheimer’s disease. Behav Brain 
Res. 2016; 296: 109-17. doi: 10.1016/j.bbr.2015.09.003.
15. Wilkins HM, Swerdlow RH. Relationships Between 
Mitochondria and Neuroinflammation: Implications for 
Alzheimer’s Disease. Curr Top Med Chem. 2016; 16: 849-
57. doi: 
16. Naidoo R, Knapp M. Studies of lipid peroxidation products 
in cerebrospinal fluid and serum in multiple sclerosis and 
other conditions. Clin Chem. 1992; 38: 2449-54. doi: 
17. Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM. 
Alzheimer’s amyloid precursor protein alpha-secretase is 
inhibited by hydroxamic acid-based zinc metalloprotease 
inhibitors: similarities to the angiotensin converting enzyme 
secretase. Biochemistry. 1998; 37: 1680-5. doi: 10.1021/
bi972034y.
18. Parvathy S, Turner AJ, Hooper NM. Inhibition of alpha-
Secretase by Zinc Metalloproteinase Inhibitors. Methods 
Mol Med. 2000; 32: 203-15. doi: 10.1385/1-59259-195-
7:203.
19. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, 
Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant 
MB, Saftig P, et al. beta-Secretase (BACE1) inhibition 
causes retinal pathology by vascular dysregulation and 
accumulation of age pigment. EMBO Mol Med. 2012; 4: 
980-91. doi: 10.1002/emmm.201101084.
20. Ghosh AK, Osswald HL. BACE1 (beta-secretase) inhibitors 
for the treatment of Alzheimer’s disease. Chem Soc Rev. 
2014; 43: 6765-813. doi: 10.1039/c3cs60460h.
21. Laird FM, Cai H, Savonenko AV, Farah MH, He K, 
Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, 
Borchelt DR, Price DL, Lee HK, et al. BACE1, a major 
determinant of selective vulnerability of the brain to 
amyloid-beta amyloidogenesis, is essential for cognitive, 
emotional, and synaptic functions. J Neurosci. 2005; 25: 
11693-709. doi: 10.1523/JNEUROSCI.2766-05.2005.
Oncotarget64600www.impactjournals.com/oncotarget
22. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry 
R, Disterhoft JF, Vassar R. BACE1 gene deletion prevents 
neuron loss and memory deficits in 5XFAD APP/PS1 
transgenic mice. Neurobiol Dis. 2007; 26: 134-45. doi: 
10.1016/j.nbd.2006.12.008.
23. Selkoe DJ, Wolfe MS. In search of gamma-secretase: 
presenilin at the cutting edge. Proc Natl Acad Sci U S A. 
2000; 97: 5690-2. doi: 
24. Haxaire C, Turpin FR, Potier B, Kervern M, Sinet PM, 
Barbanel G, Mothet JP, Dutar P, Billard JM. Reversal of 
age-related oxidative stress prevents hippocampal synaptic 
plasticity deficits by protecting D-serine-dependent NMDA 
receptor activation. Aging Cell. 2012; 11: 336-44. doi: 
10.1111/j.1474-9726.2012.00792.x.
25. Vincent AJ, Gasperini R, Foa L, Small DH. Astrocytes 
in Alzheimer’s disease: emerging roles in calcium 
dysregulation and synaptic plasticity. J Alzheimers Dis. 
2010; 22: 699-714. doi: 10.3233/JAD-2010-101089.
26. Zhang H, Liu J, Sun S, Pchitskaya E, Popugaeva E, 
Bezprozvanny I. Calcium signaling, excitability, and 
synaptic plasticity defects in a mouse model of Alzheimer’s 
disease. J Alzheimers Dis. 2015; 45: 561-80. doi: 10.3233/
JAD-142427.
27. Selkoe DJ, Schenk D. Alzheimer’s disease: molecular 
understanding predicts amyloid-based therapeutics. Annu 
Rev Pharmacol Toxicol. 2003; 43: 545-84. doi: 10.1146/
annurev.pharmtox.43.100901.140248.
28. Selkoe DJ. Alzheimer’s disease is a synaptic failure. 
Science. 2002; 298: 789-91. doi: 10.1126/science.1074069.
29. Garelick MG, Kennedy BK. TOR on the brain. 
Exp Gerontol. 2011; 46: 155-63. doi: 10.1016/j.
exger.2010.08.030.
30. Pagliarulo C, De Vito V, Picariello G, Colicchio R, Pastore 
G, Salvatore P, Volpe MG. Inhibitory effect of pomegranate 
(Punica granatum L.) polyphenol extracts on the bacterial 
growth and survival of clinical isolates of pathogenic 
Staphylococcus aureus and Escherichia coli. Food Chem. 
2016; 190: 824-31. doi: 10.1016/j.foodchem.2015.06.028.
31. Li X, Wasila H, Liu L, Yuan T, Gao Z, Zhao B, Ahmad I. 
Physicochemical characteristics, polyphenol compositions 
and antioxidant potential of pomegranate juices from 
10 Chinese cultivars and the environmental factors 
analysis. Food Chem. 2015; 175: 575-84. doi: 10.1016/j.
foodchem.2014.12.003.
32. Trigueros L, Wojdylo A, Sendra E. Antioxidant activity and 
protein-polyphenol interactions in a pomegranate (Punica 
granatum L.) yogurt. J Agric Food Chem. 2014; 62: 6417-
25. doi: 10.1021/jf501503h.
33. Chen B, Longtine MS, Nelson DM. Punicalagin, a 
polyphenol in pomegranate juice, downregulates p53 
and attenuates hypoxia-induced apoptosis in cultured 
human placental syncytiotrophoblasts. Am J Physiol 
Endocrinol Metab. 2013; 305: E1274-80. doi: 10.1152/
ajpendo.00218.2013.
34. Yan H, Peng KJ, Wang QL, Gu ZY, Lu YQ, Zhao J, Xu 
F, Liu YL, Tang Y, Deng FM, Zhou P, Jin JG, Wang XC. 
Effect of pomegranate peel polyphenol gel on cutaneous 
wound healing in alloxan-induced diabetic rats. Chin Med 
J (Engl). 2013; 126: 1700-6. doi: 
35. Neyrinck AM, Van Hee VF, Bindels LB, De Backer 
F, Cani PD, Delzenne NM. Polyphenol-rich extract of 
pomegranate peel alleviates tissue inflammation and 
hypercholesterolaemia in high-fat diet-induced obese mice: 
potential implication of the gut microbiota. Br J Nutr. 2013; 
109: 802-9. doi: 10.1017/S0007114512002206.
36. Tsang C, Smail NF, Almoosawi S, Davidson I, Al-Dujaili 
EA. Intake of polyphenol-rich pomegranate pure juice 
influences urinary glucocorticoids, blood pressure and 
homeostasis model assessment of insulin resistance in 
human volunteers. J Nutr Sci. 2012; 1: e9. doi: 10.1017/
jns.2012.10.
37. Haidari M, Ali M, Ward Casscells S, 3rd, Madjid M. 
Pomegranate (Punica granatum) purified polyphenol 
extract inhibits influenza virus and has a synergistic effect 
with oseltamivir. Phytomedicine. 2009; 16: 1127-36. doi: 
10.1016/j.phymed.2009.06.002.
38. Rasheed Z, Akhtar N, Anbazhagan AN, Ramamurthy S, 
Shukla M, Haqqi TM. Polyphenol-rich pomegranate fruit 
extract (POMx) suppresses PMACI-induced expression of 
pro-inflammatory cytokines by inhibiting the activation of 
MAP Kinases and NF-kappaB in human KU812 cells. J 
Inflamm (Lond). 2009; 6: 1. doi: 10.1186/1476-9255-6-1.
39. Faria A, Monteiro R, Azevedo I, Calhau C. Comment 
on safety and antioxidant activity of a pomegranate 
ellagitannin-enriched polyphenol dietary supplement in 
overweight individuals with increased waist size. J Agric 
Food Chem. 2008; 56: 12143-4; author reply 5-6. doi: 
10.1021/jf802383q.
40. Heber D, Seeram NP, Wyatt H, Henning SM, Zhang Y, 
Ogden LG, Dreher M, Hill JO. Safety and antioxidant 
activity of a pomegranate ellagitannin-enriched polyphenol 
dietary supplement in overweight individuals with increased 
waist size. J Agric Food Chem. 2007; 55: 10050-4. doi: 
10.1021/jf071689v.
41. Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M, 
Amir R. Antioxidant activity, polyphenol content, and 
related compounds in different fruit juices and homogenates 
prepared from 29 different pomegranate accessions. J Agric 
Food Chem. 2007; 55: 9559-70. doi: 10.1021/jf071413n.
42. Zaid MA, Afaq F, Syed DN, Dreher M, Mukhtar H. 
Inhibition of UVB-mediated oxidative stress and markers 
of photoaging in immortalized HaCaT keratinocytes 
by pomegranate polyphenol extract POMx. Photochem 
Photobiol. 2007; 83: 882-8. doi: 10.1111/j.1751-
1097.2007.00157.x.
43. Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan 
FA. Evaluation of the bioavailability and metabolism in 
the rat of punicalagin, an antioxidant polyphenol from 
pomegranate juice. Eur J Nutr. 2003; 42: 18-28. doi: 
Oncotarget64601www.impactjournals.com/oncotarget
10.1007/s00394-003-0396-4.
44. Wang J, Rong X, Um IS, Yamahara J, Li Y. 55-week 
treatment of mice with the unani and ayurvedic medicine 
pomegranate flower ameliorates ageing-associated 
insulin resistance and skin abnormalities. Evid Based 
Complement Alternat Med. 2012; 2012: 350125. doi: 
10.1155/2012/350125.
45. West T, Atzeva M, Holtzman DM. Pomegranate 
polyphenols and resveratrol protect the neonatal brain 
against hypoxic-ischemic injury. Dev Neurosci. 2007; 29: 
363-72. doi: 10.1159/000105477.
46. Loren DJ, Seeram NP, Schulman RN, Holtzman DM. 
Maternal dietary supplementation with pomegranate juice 
is neuroprotective in an animal model of neonatal hypoxic-
ischemic brain injury. Pediatr Res. 2005; 57: 858-64. doi: 
10.1203/01.PDR.0000157722.07810.15.
47. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav 
R, Braidy N, Manivasagam T, Guillemin GJ. Pomegranate 
from Oman Alleviates the Brain Oxidative Damage in 
Transgenic Mouse Model of Alzheimer’s disease. J Tradit 
Complement Med. 2014; 4: 232-8. doi: 10.4103/2225-
4110.139107.
48. Hartman RE, Shah A, Fagan AM, Schwetye KE, 
Parsadanian M, Schulman RN, Finn MB, Holtzman 
DM. Pomegranate juice decreases amyloid load and 
improves behavior in a mouse model of Alzheimer’s 
disease. Neurobiol Dis. 2006; 24: 506-15. doi: 10.1016/j.
nbd.2006.08.006.
49. Subash S, Braidy N, Essa MM, Zayana AB, Ragini V, Al-
Adawi S, Al-Asmi A, Guillemin GJ. Long-term (15 mo) 
dietary supplementation with pomegranates from Oman 
attenuates cognitive and behavioral deficits in a transgenic 
mice model of Alzheimer’s disease. Nutrition. 2015; 31: 
223-9. doi: 10.1016/j.nut.2014.06.004.
50. Agarwal S, Tannenberg RK, Dodd PR. Reduced expression 
of the inhibitory synapse scaffolding protein gephyrin in 
Alzheimer’s disease. J Alzheimers Dis. 2008; 14: 313-21. 
doi: 
51. Kallop DY, Meilandt WJ, Gogineni A, Easley-Neal C, Wu 
T, Jubb AM, Yaylaoglu M, Shamloo M, Tessier-Lavigne 
M, Scearce-Levie K, Weimer RM. A death receptor 
6-amyloid precursor protein pathway regulates synapse 
density in the mature CNS but does not contribute to 
Alzheimer’s disease-related pathophysiology in murine 
models. J Neurosci. 2014; 34: 6425-37. doi: 10.1523/
JNEUROSCI.4963-13.2014.
52. Siman R, Cocca R, Dong Y. The mTOR Inhibitor 
Rapamycin Mitigates Perforant Pathway Neurodegeneration 
and Synapse Loss in a Mouse Model of Early-Stage 
Alzheimer-Type Tauopathy. PLoS One. 2015; 10: 
e0142340. doi: 10.1371/journal.pone.0142340.
53. Retraction notice to: SIRT1 suppresses beta-amyloid 
production by activating the alpha-secretase gene ADAM10. 
Cell. 2014; 158: 959. doi: 10.1016/j.cell.2014.06.035.
54. Allinson TM, Parkin ET, Condon TP, Schwager SL, 
Sturrock ED, Turner AJ, Hooper NM. The role of ADAM10 
and ADAM17 in the ectodomain shedding of angiotensin 
converting enzyme and the amyloid precursor protein. 
Eur J Biochem. 2004; 271: 2539-47. doi: 10.1111/j.1432-
1033.2004.04184.x.
55. Harris B, Pereira I, Parkin E. Targeting ADAM10 to 
lipid rafts in neuroblastoma SH-SY5Y cells impairs 
amyloidogenic processing of the amyloid precursor 
protein. Brain Res. 2009; 1296: 203-15. doi: 10.1016/j.
brainres.2009.07.105.
56. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, 
Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF. 
ADAM10 is the physiologically relevant, constitutive 
alpha-secretase of the amyloid precursor protein in primary 
neurons. EMBO J. 2010; 29: 3020-32. doi: 10.1038/
emboj.2010.167.
57. Marcinkiewicz M, Seidah NG. Coordinated expression 
of beta-amyloid precursor protein and the putative beta-
secretase BACE and alpha-secretase ADAM10 in mouse 
and human brain. J Neurochem. 2000; 75: 2133-43. doi: 
58. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski 
AN, Kim DY, Tanzi RE. ADAM10 missense mutations 
potentiate beta-amyloid accumulation by impairing 
prodomain chaperone function. Neuron. 2013; 80: 385-401. 
doi: 10.1016/j.neuron.2013.08.035.
59. Xu D, Sharma C, Hemler ME. Tetraspanin12 regulates 
ADAM10-dependent cleavage of amyloid precursor 
protein. FASEB J. 2009; 23: 3674-81. doi: 10.1096/fj.09-
133462.
60. Kwak H-M, Jeon S-Y, Sohng B-H, Kim J-G, Lee J-M, 
Lee K-B, Jeong H-H, Hur J-M, Kang Y-H, Song K-S. 
β-Secretase (BACE1) inhibitors from pomegranate (Punica 
granatum) husk. Archives of pharmacal research. 2005; 28: 
1328-32. doi: 
61. de Oliveira MR, Nabavi SM, Braidy N, Setzer WN, 
Ahmad T, SF N. Quercetin and the mitochondria: A 
mechanistic view. Biotechnol Adv. 2015. doi: 10.1016/j.
biotechadv.2015.12.014.
62. Kwak HM, Jeon SY, Sohng BH, Kim JG, Lee JM, Lee KB, 
Jeong HH, Hur JM, Kang YH, Song KS. beta-Secretase 
(BACE1) inhibitors from pomegranate (Punica granatum) 
husk. Arch Pharm Res. 2005; 28: 1328-32. doi: 
63. Braidy N, Selvaraju S, Essa MM, Vaishnav R, Al-Adawi 
S, Al-Asmi A, Al-Senawi H, Abd Alrahman Alobaidy 
A, Lakhtakia R, Guillemin GJ. Neuroprotective effects 
of a variety of pomegranate juice extracts against MPTP-
induced cytotoxicity and oxidative stress in human primary 
neurons. Oxid Med Cell Longev. 2013; 2013: 685909. doi: 
10.1155/2013/685909.
64. Weyl-Feinstein S, Markovics A, Eitam H, Orlov A, 
Yishay M, Agmon R, Miron J, Izhaki I, Shabtay A. Short 
communication: effect of pomegranate-residue supplement 
on Cryptosporidium parvum oocyst shedding in neonatal 
calves. J Dairy Sci. 2014; 97: 5800-5. doi: 10.3168/
Oncotarget64602www.impactjournals.com/oncotarget
jds.2013-7136.
65. Dulcich MS, Hartman RE. Pomegranate supplementation 
improves affective and motor behavior in mice after 
radiation exposure. Evid Based Complement Alternat Med. 
2013; 2013: 940830. doi: 10.1155/2013/940830.
66. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner 
D, Ma L, Messina A, Huang Z, Wu J, Oddo S. Reducing 
Ribosomal Protein S6 Kinase 1 Expression Improves 
Spatial Memory and Synaptic Plasticity in a Mouse Model 
of Alzheimer’s Disease. J Neurosci. 2015; 35: 14042-56. 
doi: 10.1523/JNEUROSCI.2781-15.2015.
67. Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt 
A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, 
Hansson O, Andreasson U, Teunissen CE, Scheltens P, 
et al. Cerebrospinal fluid levels of the synaptic protein 
neurogranin correlates with cognitive decline in prodromal 
Alzheimer’s disease. Alzheimers Dement. 2015; 11: 1180-
90. doi: 10.1016/j.jalz.2014.10.009.
68. Sotiropoulos I, Sousa N. Tau as the Converging Protein 
between Chronic Stress and Alzheimer’s Disease Synaptic 
Pathology. Neurodegener Dis. 2016; 16: 22-5. doi: 
10.1159/000440844.
69. Tiwari SS, d’Orange M, Troakes C, Shurovi BN, Engmann 
O, Noble W, Hortobagyi T, Giese KP. Evidence that 
the presynaptic vesicle protein CSPalpha is a key player 
in synaptic degeneration and protection in Alzheimer’s 
disease. Mol Brain. 2015; 8: 6. doi: 10.1186/s13041-015-
0096-z.
70. Muller M, Cardenas C, Mei L, Cheung KH, Foskett JK. 
Constitutive cAMP response element binding protein 
(CREB) activation by Alzheimer’s disease presenilin-
driven inositol trisphosphate receptor (InsP3R) Ca2+ 
signaling. Proc Natl Acad Sci U S A. 2011; 108: 13293-8. 
doi: 10.1073/pnas.1109297108.
71. Pugazhenthi S, Wang M, Pham S, Sze CI, Eckman CB. 
Downregulation of CREB expression in Alzheimer’s 
brain and in Abeta-treated rat hippocampal neurons. Mol 
Neurodegener. 2011; 6: 60. doi: 10.1186/1750-1326-6-60.
72. Saura CA, Valero J. The role of CREB signaling in 
Alzheimer’s disease and other cognitive disorders. Rev 
Neurosci. 2011; 22: 153-69. doi: 10.1515/RNS.2011.018.
73. Scott Bitner R. Cyclic AMP response element-binding 
protein (CREB) phosphorylation: a mechanistic marker in 
the development of memory enhancing Alzheimer’s disease 
therapeutics. Biochem Pharmacol. 2012; 83: 705-14. doi: 
10.1016/j.bcp.2011.11.009.
74. Wang A, Bibb JA. Is CREB the angry bird that releases 
memory in Alzheimer’s? Neuropsychopharmacology. 2011; 
36: 2153-4. doi: 10.1038/npp.2011.126.
75. Yiu AP, Rashid AJ, Josselyn SA. Increasing CREB function 
in the CA1 region of dorsal hippocampus rescues the spatial 
memory deficits in a mouse model of Alzheimer’s disease. 
Neuropsychopharmacology. 2011; 36: 2169-86. doi: 
10.1038/npp.2011.107.
76. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-
Schaeffer W, Heine H, Penke B, Neumann H, Fassbender 
K. LPS receptor (CD14): a receptor for phagocytosis of 
Alzheimer’s amyloid peptide. Brain. 2005; 128: 1778-89. 
doi: 10.1093/brain/awh531.
77. Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E, 
Wyss-Coray T. Regulation of amyloid precursor protein 
processing by the Beclin 1 complex. PLoS One. 2010; 5: 
e11102. doi: 10.1371/journal.pone.0011102.
78. Lucin KM, O’Brien CE, Bieri G, Czirr E, Mosher KI, 
Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah 
E, Wyss-Coray T. Microglial beclin 1 regulates retromer 
trafficking and phagocytosis and is impaired in Alzheimer’s 
disease. Neuron. 2013; 79: 873-86. doi: 10.1016/j.
neuron.2013.06.046.
79. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan 
R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine 
B, Wyss-Coray T. The autophagy-related protein beclin 1 
shows reduced expression in early Alzheimer disease and 
regulates amyloid beta accumulation in mice. J Clin Invest. 
2008; 118: 2190-9. doi: 10.1172/JCI33585.
80. Cho DH, Jo YK, Hwang JJ, Lee YM, Roh SA, Kim JC. 
Caspase-mediated cleavage of ATG6/Beclin-1 links 
apoptosis to autophagy in HeLa cells. Cancer Lett. 2009; 
274: 95-100. doi: 10.1016/j.canlet.2008.09.004.
81. Lee CC, Huang CC, Hsu KS. Insulin promotes dendritic 
spine and synapse formation by the PI3K/Akt/mTOR and 
Rac1 signaling pathways. Neuropharmacology. 2011; 61: 
867-79. doi: 10.1016/j.neuropharm.2011.06.003.
82. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li 
XY, Aghajanian G, Duman RS. mTOR-dependent synapse 
formation underlies the rapid antidepressant effects of 
NMDA antagonists. Science. 2010; 329: 959-64. doi: 
10.1126/science.1190287.
83. Bettio LE, Cunha MP, Budni J, Pazini FL, Oliveira A, Colla 
AR, Rodrigues AL. Guanosine produces an antidepressant-
like effect through the modulation of NMDA receptors, 
nitric oxide-cGMP and PI3K/mTOR pathways. Behav Brain 
Res. 2012; 234: 137-48. doi: 10.1016/j.bbr.2012.06.021.
84. Burket JA, Benson AD, Tang AH, Deutsch SI. NMDA 
receptor activation regulates sociability by its effect on 
mTOR signaling activity. Prog Neuropsychopharmacol 
Biol Psychiatry. 2015; 60: 60-5. doi: 10.1016/j.
pnpbp.2015.02.009.
85. Huang Y, Kang BN, Tian J, Liu Y, Luo HR, Hester 
L, Snyder SH. The cationic amino acid transporters 
CAT1 and CAT3 mediate NMDA receptor activation-
dependent changes in elaboration of neuronal processes 
via the mammalian target of rapamycin mTOR 
pathway. J Neurosci. 2007; 27: 449-58. doi: 10.1523/
JNEUROSCI.4489-06.2007.
86. Tang J, Xue W, Xia B, Ren L, Tao W, Chen C, Zhang H, 
Wu R, Wang Q, Wu H, Duan J, Chen G. Involvement of 
normalized NMDA receptor and mTOR-related signaling 
in rapid antidepressant effects of Yueju and ketamine on 
Oncotarget64603www.impactjournals.com/oncotarget
chronically stressed mice. Sci Rep. 2015; 5: 13573. doi: 
10.1038/srep13573.
87. Wang Y, Wang W, Li D, Li M, Wang P, Wen J, Liang 
M, Su B, Yin Y. IGF-1 alleviates NMDA-induced 
excitotoxicity in cultured hippocampal neurons against 
autophagy via the NR2B/PI3K-AKT-mTOR pathway. J 
Cell Physiol. 2014; 229: 1618-29. doi: 10.1002/jcp.24607.
88. Dai L, Zhuang L, Zhang B, Wang F, Chen X, Xia C, 
Zhang B. DAG/PKCdelta and IP3/Ca(2+)/CaMK IIbeta 
Operate in Parallel to Each Other in PLCgamma1-
Driven Cell Proliferation and Migration of Human 
Gastric Adenocarcinoma Cells, through Akt/mTOR/S6 
Pathway. Int J Mol Sci. 2015; 16: 28510-22. doi: 10.3390/
ijms161226116.
89. Nicolini C, Fahnestock M. Decreased mTOR signaling 
via p70S6K/eIF4B is associated with loss of the excitatory 
postsynaptic marker PSD-95 in autism. Int J Dev Neurosci. 
2015; 47: 32. doi: 10.1016/j.ijdevneu.2015.04.093.
90. Giovannini MG, Lana D, Pepeu G. The integrated role of 
ACh, ERK and mTOR in the mechanisms of hippocampal 
inhibitory avoidance memory. Neurobiol Learn Mem. 2015; 
119: 18-33. doi: 10.1016/j.nlm.2014.12.014.
91. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, 
Allison JP. Friends not foes: CTLA-4 blockade and mTOR 
inhibition cooperate during CD8+ T cell priming to promote 
memory formation and metabolic readiness. J Immunol. 
2015; 194: 2089-98. doi: 10.4049/jimmunol.1402390.
92. Setoguchi R, Matsui Y, Mouri K. mTOR signaling promotes 
a robust and continuous production of IFN-gamma by 
human memory CD8+ T cells and their proliferation. Eur J 
Immunol. 2015; 45: 893-902. doi: 10.1002/eji.201445086.
93. Sowell RT, Marzo AL. Resident-Memory CD8 T 
Cells and mTOR: Generation, Protection, and Clinical 
Importance. Front Immunol. 2015; 6: 38. doi: 10.3389/
fimmu.2015.00038.
94. Su ZW, Liao JY, Zhang H, Zhang T, Wu F, Tian XH, 
Zhang FT, Sun WW, Cui QL. Postnatal high-protein 
diet improves learning and memory in premature rats via 
activation of mTOR signaling. Brain Res. 2015; 1611: 1-7. 
doi: 10.1016/j.brainres.2015.01.052.
95. Xiong H, Casse F, Zhou Y, Zhou M, Xiong ZQ, Joels M, 
Martin S, Krugers HJ. mTOR is essential for corticosteroid 
effects on hippocampal AMPA receptor function and fear 
memory. Learn Mem. 2015; 22: 577-83. doi: 10.1101/
lm.039420.115.
96. C ON. PI3-kinase/Akt/mTOR signaling: impaired on/
off switches in aging, cognitive decline and Alzheimer’s 
disease. Exp Gerontol. 2013; 48: 647-53. doi: 10.1016/j.
exger.2013.02.025.
97. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-
Aranda MF, Silva AJ, Oddo S. mTOR regulates tau 
phosphorylation and degradation: implications for 
Alzheimer’s disease and other tauopathies. Aging Cell. 
2013; 12: 370-80. doi: 10.1111/acel.12057.
98. Cai Z, Chen G, He W, Xiao M, Yan LJ. Activation of 
mTOR: a culprit of Alzheimer’s disease? Neuropsychiatr 
Dis Treat. 2015; 11: 1015-30. doi: 10.2147/NDT.S75717.
99. Chano T, Okabe H, Hulette CM. RB1CC1 insufficiency 
causes neuronal atrophy through mTOR signaling 
alteration and involved in the pathology of Alzheimer’s 
diseases. Brain Res. 2007; 1168: 97-105. doi: 10.1016/j.
brainres.2007.06.075.
100. Fant X, Durieu E, Chicanne G, Payrastre B, Sbrissa D, 
Shisheva A, Limanton E, Carreaux F, Bazureau JP, Meijer 
L. cdc-like/dual-specificity tyrosine phosphorylation-
regulated kinases inhibitor leucettine L41 induces mTOR-
dependent autophagy: implication for Alzheimer’s 
disease. Mol Pharmacol. 2014; 85: 441-50. doi: 10.1124/
mol.113.090837.
101. Galvan V, Hart MJ. Vascular mTOR-dependent 
mechanisms linking the control of aging to Alzheimer’s 
disease. Biochim Biophys Acta. 2015. doi: 10.1016/j.
bbadis.2015.11.010.
102. Gouras GK. mTOR: at the crossroads of aging, chaperones, 
and Alzheimer’s disease. J Neurochem. 2013; 124: 747-8. 
doi: 10.1111/jnc.12098.
103. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, 
Perault-Pochat MC, Gil R, Pradier L, Hugon J. mTOR/
p70S6k signalling alteration by Abeta exposure as well 
as in APP-PS1 transgenic models and in patients with 
Alzheimer’s disease. J Neurochem. 2005; 94: 215-25. doi: 
10.1111/j.1471-4159.2005.03187.x.
104. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels 
of mTOR and its downstream targets 4E-BP1, eEF2, and 
eEF2 kinase in relationships with tau in Alzheimer’s disease 
brain. FEBS J. 2005; 272: 4211-20. doi: 10.1111/j.1742-
4658.2005.04833.x.
105. Liu H, Qiu H, Xiao Q, Le W. Chronic Hypoxia-Induced 
Autophagy Aggravates the Neuropathology of Alzheimer’s 
Disease through AMPK-mTOR Signaling in the APPSwe/
PS1dE9 Mouse Model. J Alzheimers Dis. 2015; 48: 1019-
32. doi: 10.3233/JAD-150303.
106. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, 
Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK. 
Dysregulation of the mTOR pathway mediates impairment 
of synaptic plasticity in a mouse model of Alzheimer’s 
disease. PLoS One. 2010; 5. doi: 10.1371/journal.
pone.0012845.
107. Ma Y, Wu D, Zhang W, Liu J, Chen S, Hua B. Investigation 
of PI3K/PKB/mTOR/S6K1 signaling pathway in 
relationship of type 2 diabetes and Alzheimer’s disease. Int 
J Clin Exp Med. 2015; 8: 18581-90. doi: 
108. Ma YQ, Wu DK, Liu JK. mTOR and tau phosphorylated 
proteins in the hippocampal tissue of rats with type 2 
diabetes and Alzheimer’s disease. Mol Med Rep. 2013; 7: 
623-7. doi: 10.3892/mmr.2012.1186.
Oncotarget64604www.impactjournals.com/oncotarget
109. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson 
MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R, Hugon 
J. Activated mTOR and PKR kinases in lymphocytes 
correlate with memory and cognitive decline in Alzheimer’s 
disease. Dement Geriatr Cogn Disord. 2006; 22: 320-6. doi: 
10.1159/000095562.
110. Pei JJ, Hugon J. mTOR-dependent signalling in 
Alzheimer’s disease. J Cell Mol Med. 2008; 12: 2525-32. 
doi: 10.1111/j.1582-4934.2008.00509.x.
111. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza 
O, Bredesen D, Richardson A, Strong R, Galvan V. 
Inhibition of mTOR by rapamycin abolishes cognitive 
deficits and reduces amyloid-beta levels in a mouse model 
of Alzheimer’s disease. PLoS One. 2010; 5: e9979. doi: 
10.1371/journal.pone.0009979.
112. Sun YX, Ji X, Mao X, Xie L, Jia J, Galvan V, Greenberg 
DA, Jin K. Differential activation of mTOR complex 1 
signaling in human brain with mild to severe Alzheimer’s 
disease. J Alzheimers Dis. 2014; 38: 437-44. doi: 10.3233/
JAD-131124.
113. Tang Z, Ioja E, Bereczki E, Hultenby K, Li C, Guan Z, 
Winblad B, Pei JJ. mTor mediates tau localization and 
secretion: Implication for Alzheimer’s disease. Biochim 
Biophys Acta. 2015; 1853: 1646-57. doi: 10.1016/j.
bbamcr.2015.03.003.
114. Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L. 
Targeting the mTOR signaling network for Alzheimer’s 
disease therapy. Mol Neurobiol. 2014; 49: 120-35. doi: 
10.1007/s12035-013-8505-8.
115. Wang S, Wu J, Nie SD, Bereczki E, Pei JJ. Dysregulated 
mTOR-dependent signaling in neurodegeneration or 
carcinogenesis: implication for Alzheimer’s disease and 
brain tumors. J Alzheimers Dis. 2013; 37: 495-505. doi: 
10.3233/JAD-130641.
116. Yates SC, Zafar A, Hubbard P, Nagy S, Durant S, Bicknell 
R, Wilcock G, Christie S, Esiri MM, Smith AD, Nagy 
Z. Dysfunction of the mTOR pathway is a risk factor for 
Alzheimer’s disease. Acta Neuropathol Commun. 2013; 1: 
3. doi: 10.1186/2051-5960-1-3.
117. Natunen T, Takalo M, Kemppainen S, Leskela S, Marttinen 
M, Kurkinen KM, Pursiheimo JP, Sarajarvi T, Viswanathan 
J, Gabbouj S, Solje E, Tahvanainen E, Pirttimaki T, et al. 
Relationship between ubiquilin-1 and BACE1 in human 
Alzheimer’s disease and APdE9 transgenic mouse brain and 
cell-based models. Neurobiol Dis. 2016; 85: 187-205. doi: 
10.1016/j.nbd.2015.11.005.
118. Lichtenthaler FW. 2-Oxoglycosyl (“ulosyl”) and 
2-oximinoglycosyl bromides: versatile donors for the 
expedient assembly of oligosaccharides with beta-D-
mannose, beta-L-rhamnose, N-acetyl-beta-D-mannosamine, 
and N-acetyl-beta-D-mannosaminuronic acid units. Chem 
Rev. 2011; 111: 5569-609. doi: 10.1021/cr100444b.
119. Lichtenthaler SF. alpha-secretase in Alzheimer’s disease: 
molecular identity, regulation and therapeutic potential. 
J Neurochem. 2011; 116: 10-21. doi: 10.1111/j.1471-
4159.2010.07081.x.
120. Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang 
QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna 
M, Zhong JL, Dingwall C, Ferdous T, et al. ADAM9 
inhibition increases membrane activity of ADAM10 and 
controls alpha-secretase processing of amyloid precursor 
protein. J Biol Chem. 2011; 286: 40443-51. doi: 10.1074/
jbc.M111.280495.
121. Vincent B, Govitrapong P. Activation of the alpha-Secretase 
Processing of A beta PP as a Therapeutic Approach in 
Alzheimer’s Disease. Journal of Alzheimers Disease. 2011; 
24: 75-94. doi: 10.3233/Jad-2011-110218.
122. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction 
in IFN-gamma activated astroglia: a role in improving cell 
viability during oxidative stress. Redox Rep. 2000; 5: 101-
4. doi: 10.1179/135100000101535357. 
